AR082328A1 - Composicion farmaceutica que contiene derivado triptofano - Google Patents
Composicion farmaceutica que contiene derivado triptofanoInfo
- Publication number
- AR082328A1 AR082328A1 ARP110102663A ARP110102663A AR082328A1 AR 082328 A1 AR082328 A1 AR 082328A1 AR P110102663 A ARP110102663 A AR P110102663A AR P110102663 A ARP110102663 A AR P110102663A AR 082328 A1 AR082328 A1 AR 082328A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutical composition
- compound
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Composición farmacéutica que comprende por lo menos un compuesto de fórmula (1) en la cual los radicales denotan: R1 es hidrógeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-14, carboxi o C-tiocarb; en particular hidrógeno o alquilo C1-3; R2 es hidrógeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-14, carboxi o C-tiocarb; en particular hidrógeno o alquilo C1-3; R3 es hidrógeno o alquilo C1-8, en particular metilo; R4 es OH o O-alquilo C1-8, en particular OH; R5 es hidrógeno o alquilo C1-8, en particular hidrógeno; y/o una sal farmacéuticamente aceptable del mismo, y/ o una forma estereoisomérica o un derivado de la misma, y por lo menos un derivado ciclodextrina (C) farmacéuticamente aceptable y opcionalmente otros componentes (F).Reivindicación 7: Composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 6 en la cual el compuesto de fórmula (1) tiene una configuración R y el compuesto ciclodextrina (C) está seleccionado de b-ciclodextrinas hidroxialquilo-sustituidas. Reivindicación 8: Composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 7, en la cual la relación molar del compuesto de fórmula (1) y el compuesto ciclodextrina (C) está en el rango de desde 0,1:1 a 1:20. Reivindicación 9: Composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 8, en la cual la composición es una composición líquida acuosa que comprende por lo menos 70% en peso de agua y donde la concentración del compuesto de fórmula (1) está en el rango de desde 1 mg/ml a 50 mg/ml. Reivindicación 11: Composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 10 para el tratamiento de un trastorno o una enfermedad del sistema nervioso central. Reivindicación 12: Composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 10, para el tratamiento de un trastorno oftálmico o una enfermedad. Reivindicación 13: Procedimiento para la preparación de una composición farmacéutica que comprende las etapas de mezclar conjuntamente por lo menos un compuesto de fórmula (1) en el cual los radicales denotan: R1 es hidrógeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-14, carboxi o C-tiocarb; en particular hidrógeno o alquilo C1-3; R2 es hidrógeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-14, carboxi o C-tiocarb; en particular hidrógeno o alquilo C1-3; R3 es hidrógeno o alquilo C1-8, en particular metilo; R4 es OH o O-alquilo C1-8, en particular OH; R5 es hidrógeno o alquilo C1-8, en particular hidrógeno; y/o una sal farmacéuticamente aceptable del mismo y/o una forma estereoisomérica y un derivado del mismo, y por lo menos un derivado ciclodextrina farmacéuticamente aceptable (C) y opcionalmente más componentes (F). Reivindicación 15: Uso de acuerdo con la reivindicación 14, que comprende además el uso de un preservador que contiene metal, en particular tiomersal, donde la composición farmacéutica comprende un agente farmacéutico hidrofílico, donde la concentración del compuesto ciclodextrina (C) en la composición farmacéutica es de por lo menos 10 mg/ml.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36653810P | 2010-07-22 | 2010-07-22 | |
| EP10170397 | 2010-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082328A1 true AR082328A1 (es) | 2012-11-28 |
Family
ID=42727444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102663A AR082328A1 (es) | 2010-07-22 | 2011-07-22 | Composicion farmaceutica que contiene derivado triptofano |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130197053A1 (es) |
| EP (1) | EP2595625B1 (es) |
| JP (1) | JP6038786B2 (es) |
| KR (1) | KR20130102037A (es) |
| CN (1) | CN103052387A (es) |
| AR (1) | AR082328A1 (es) |
| AU (1) | AU2011281837A1 (es) |
| BR (1) | BR112013001609A2 (es) |
| CA (1) | CA2805968A1 (es) |
| MX (1) | MX2013000855A (es) |
| RU (1) | RU2013107761A (es) |
| TW (1) | TW201216960A (es) |
| WO (1) | WO2012010415A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193035A1 (en) * | 2019-04-24 | 2022-06-23 | Galimedix Therapeutics, Inc. | Indole compounds for use in neurorestoration |
| BR112022005331A2 (pt) * | 2019-09-23 | 2022-06-14 | Galimedix Therapeutics Inc | Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma |
| WO2021222888A1 (en) * | 2020-05-01 | 2021-11-04 | University Of Southern California | Cyclodextrin based anti-microbial therapy |
| IL298502A (en) * | 2020-05-24 | 2023-01-01 | Galimedix Therapeutics Inc | Crystalline forms of solvates of tryptophan derivatives, their constituent compounds and uses thereof |
| CN115340615B (zh) * | 2022-08-12 | 2023-05-02 | 同济大学 | 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| DE3615710A1 (de) * | 1986-05-09 | 1987-11-26 | Hoechst Ag | Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen |
| WO2005000193A2 (en) * | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| US7781396B2 (en) | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| AR067746A1 (es) * | 2007-08-02 | 2009-10-21 | Otsuka Pharma Co Ltd | Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol |
| EP2044951A1 (en) * | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| TW201006463A (en) | 2008-06-26 | 2010-02-16 | Merz Pharma Gmbh & Co Kgaa | Pharmaceutical compositions comprising aminocyclohexane derivatives |
| EP2437602A4 (en) * | 2009-06-05 | 2014-02-19 | Aciex Therapeutics Inc | OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE |
-
2011
- 2011-07-06 WO PCT/EP2011/061356 patent/WO2012010415A1/en active Application Filing
- 2011-07-06 CA CA2805968A patent/CA2805968A1/en not_active Abandoned
- 2011-07-06 CN CN2011800353084A patent/CN103052387A/zh active Pending
- 2011-07-06 US US13/810,729 patent/US20130197053A1/en not_active Abandoned
- 2011-07-06 JP JP2013520046A patent/JP6038786B2/ja active Active
- 2011-07-06 AU AU2011281837A patent/AU2011281837A1/en not_active Abandoned
- 2011-07-06 BR BR112013001609A patent/BR112013001609A2/pt not_active IP Right Cessation
- 2011-07-06 EP EP11729424.9A patent/EP2595625B1/en active Active
- 2011-07-06 KR KR1020137004152A patent/KR20130102037A/ko not_active Application Discontinuation
- 2011-07-06 RU RU2013107761/04A patent/RU2013107761A/ru not_active Application Discontinuation
- 2011-07-06 MX MX2013000855A patent/MX2013000855A/es not_active Application Discontinuation
- 2011-07-14 TW TW100124963A patent/TW201216960A/zh unknown
- 2011-07-22 AR ARP110102663A patent/AR082328A1/es not_active Application Discontinuation
-
2017
- 2017-12-20 US US15/848,044 patent/US20180118682A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013000855A (es) | 2013-02-27 |
| US20130197053A1 (en) | 2013-08-01 |
| CA2805968A1 (en) | 2012-01-26 |
| JP2013532638A (ja) | 2013-08-19 |
| EP2595625B1 (en) | 2016-04-20 |
| EP2595625A1 (en) | 2013-05-29 |
| WO2012010415A1 (en) | 2012-01-26 |
| TW201216960A (en) | 2012-05-01 |
| BR112013001609A2 (pt) | 2017-04-04 |
| AU2011281837A1 (en) | 2013-03-14 |
| CN103052387A (zh) | 2013-04-17 |
| RU2013107761A (ru) | 2014-08-27 |
| US20180118682A1 (en) | 2018-05-03 |
| KR20130102037A (ko) | 2013-09-16 |
| JP6038786B2 (ja) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| AR082328A1 (es) | Composicion farmaceutica que contiene derivado triptofano | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015023761A2 (pt) | moduladores de molécula pequena de pcsk9 e seus métodos e usos | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| PE20181519A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
| BR112014010590A2 (pt) | 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
| CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
| DOP2013000314A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| BR112015020222A8 (pt) | composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas | |
| AR075614A1 (es) | Piperidinas 1, 4-disustituidas, una composicion farmaceutica que las comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores v1a de vasopresina. | |
| AR091520A1 (es) | Inhibidores piranopiridona de tanquirasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |